Search results
Results from the WOW.Com Content Network
He spent eight years working in Novartis Vaccines, and was the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17] From 2014 to 2016, he was the Global Head of Development for Novartis Pharmaceuticals.
Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch. [175] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy ...
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
Swiss drugmaker Novartis <NOVN.S> has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1. The statement said Chouraqui had "consistently ...
Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.
Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010 [7] by his predecessor and Chairman Daniel Vasella. [8]During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods would help to realize improvements in Novartis ...
Novartis AG (NYSE: NVS) has appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down after seven years ...
Thomas Ebeling (born February 9, 1959, in Hanover [1]) is a German executive and the former CEO of ProSiebenSat.1 Media and Novartis. Thomas Ebeling studied psychology in Hamburg. After graduating in 1987, [2] he started at Reemtsma. [3] In 1991, he switched to Pepsi-Cola Germany as a Marketing Manager. From 1994, he served as the National ...